Abstract:Abstract Abstract 3635 Objective: It has been shown that oroxylin A, a monoflavonoid extracted from the root of the Chinese herb medicine Scutellaria baicalensis, could effectively inhibit the proliferation of several cancer cell lines. However, little is known about the effect of oroxylin A on leukemic cells. In the current study the effects of oroxylin A were analized on growth, differentiation and cell cycle of myeloid leukemic cell lines. Methods: This study used AML cell lines including NB4, U937 and HL60. Expression and distribution of the proteins were analyzed by flow cytometry, western blots and Immunofluoresence assay. The growth inhibition effect of the drug was evaluated by MTT and cell cycle assay. The differentiation of cells was estimated by Giemsa stain and NBT reduction assay. Results: The growth of U937, HL60 and NB4 cells incubated with oroxylin A was inhibited in a time- and concentration-dependent manner but no apoptosis effect could be observed. Moreover, oroxylin A induced monocytic differentiation and G0/G1 phase arrest in U937 and HL60 cells, meanwhile, the expresstion of PPARγ, a nuclear receptor correlated with monocytic differentiation, was enhanced specificly and a nuclear accumulation of PPARγ was induced. Effects of differentiation and the upregulation of p21 could be attenuated by GW9662, a specific inhibitor of PPARγ. Oroxylin A dramatically displayed synergistic effect with ATRA or VD3 on growth and differentiation of NB4 or U937 cells respectively. We investigated the phosphorylation of RXRα, a nuclear receptor which assists RARα, PPARγ and VDR to exert differentiation effects through heterodimerize with them, was inhibited especially in nuclear of NB4, U937 and HL60 cells treated with oroxylin A. Activition of MAPK/ERK pathway, which is responsible for phosphorylation of RXRα, was also inhibited by oroxylin A. Conclusion: The results showed here demonstrated that oroxylin A could induce growth inhibition, G0/G1 phase arrest and differentiation of U937 and HL60 and show synergistic effects in combination with ATRA in NB4 and with VD3 in U937 cells via potential inhibition effect on phosphorylation of RXRα. Disclosures: No relevant conflicts of interest to declare.

Oroxylin A Inhibits ATRA-induced IL-6 Expression Involved in Retinoic Acid Syndrome by Down-Regulating CHOP

Oroxylin A Induce Differentiation And G0/G1 Phase Arrest Of Acute Myeloid Leukemia (Aml)Cells Via Effects On Ppar Gamma/Rxr Alpha Heterodimers

Oroxylin A, A Natural Compound, Mitigates The Negative Effects Of Tnf Alpha-Treated Acute Myelogenous Leukemia Cells

Oroxylin A Has Therapeutic Potential in Acute Myelogenous Leukemia by Dual Effects Targeting PPARγ and RXRα

CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.

Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment

Oroxylin a Heightens Tumor Necrosis Factor A-Induced Differentiation Effects on Acute Myeloid Leukemia Cells Via Modulation on AKT and NF-Kb Pathways Involving RXRa

Oroxylin A, a natural anticancer flavonoid compound, induces differentiation of t(8;21)-positive Kasumi-1 and primary acute myeloid leukemia cells

Oroxylin a Inhibits the Protection O F Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway

The Role of Nrf2 and Apoptotic Signaling Pathways in Oroxylin A-Mediated Responses in Hct-116 Colorectal Adenocarcinoma Cells and Xenograft Tumors

Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest

Oroxylin A inhibits hypoxia-induced invasion and migration of MCF-7 cells by suppressing the Notch pathway.

Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells.

Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells.

Oroxylin A Sensitizes Non-Small Cell Lung Cancer Cells to Anoikis Via Glucose-Deprivation-like Mechanisms: C-Src and Hexokinase II.

Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription

Oroxylin a Reverses Multi‐drug Resistance of Human Hepatoma BEL7402/5‐FU Cells Via Downregulation of P‐glycoprotein Expression by Inhibiting NF‐κB Signaling Pathway

Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation

Oroxylin A Inhibits Matrix Metalloproteinase-2/9 Expression and Activation by Up-Regulating Tissue Inhibitor of Metalloproteinase-2 and Suppressing the ERK1/2 Signaling Pathway

Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression

Oroxylin A Exerts Anti-Inflammatory Activity on Lipopolysaccharide-Induced Mouse Macrophage Via Nrf2/ARE Activation.